Starling Oncology, Inc. (STLN) Guidance & Earnings Results

On 2026-08-06 Starling Oncology, Inc. raised guidance: "FY26 revenue raised to $650-670M from $630-650M; FY26 gross profit raised to $105-110M from $97-107M; FY26 Adjusted EBITDA raised to $2-7M from $0-9M; FY26 Free Cash Flow unchanged at $5-15M; Q3 2026 Adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

STLNStarling Oncology, Inc.Follow STLN — free

Medical Care Facilities · Healthcare

—

Price chart with a free account

Market cap: 683.9M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	FY26 revenue raised to $650-670M from $630-650M; FY26 gross profit raised to $105-110M from $97-107M; FY26 Adjusted EBITDA raised to $2-7M from $0-9M; FY26 Free Cash Flow unchanged at $5-15M; Q3 2026 Adjusted EBITDA $0.5-1.5M · full year
7 May 26	Reaffirmed	FY2026 revenue $630-650M (unchanged); gross profit $97-107M (unchanged); Adjusted EBITDA $0-9M (unchanged); Free Cash Flow raised to $5-15M from $(15)-$5M; Q2 2026 Adjusted EBITDA $(1)-$1M · full year
12 Mar 26	Raised	FY2026 revenue $630-650M; gross profit $97-107M; Adj. EBITDA $0-9M; FCF -$15 to $5M; capitated revenue ~$150M; Q1 Adj. EBITDA -$1 to -$3M · full year
12 Jan 26	Reaffirmed	2026 revenue $630-650M (+28% YoY); Adjusted EBITDA $0-9M; longer-term 20% annual revenue growth through 2028 · full year
13 Nov 25	Raised	FY25 revenue raised to $495-505M from $460-480M; Adjusted EBITDA narrowed to -$11 to -$13M from -$8 to -$17M; Q4 Adjusted EBITDA expected $0-2M · full year
13 Aug 25	Reaffirmed	FY2025 revenue $460-480M; gross profit $73-82M; Adjusted EBITDA $(8)-$(17)M; free cash flow $(12)-$(21)M; Q3 2025 Adjusted EBITDA $(2.5)-$(3.5)M · full year

Starling Oncology, Inc. — questions

What guidance did Starling Oncology, Inc. give?: On 2026-08-06: "FY26 revenue raised to $650-670M from $630-650M; FY26 gross profit raised to $105-110M from $97-107M; FY26 Adjusted EBITDA raised to $2-7M from $0-9M; FY26 Free Cash Flow unchanged at $5-15M; Q3 2026 Adjusted EBITDA $0.5-1.5M"
When does Starling Oncology, Inc. report earnings?: Starling Oncology, Inc.'s next earnings report is expected on 2026-11-11.

Every figure on this page comes from Starling Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.